Actively Recruiting

Age: 0 - 15Years
All Genders
NCT04286360

Hematological Anomalies in Children With Rasopathy

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2024-06-04

300

Participants Needed

14

Research Sites

468 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative disorders. These anomalies may spontaneously disappear or persist, sometimes leading to juvenile myelomonocytic leukemia. Guidelines for initial screening and subsequent hematological follow-up have recently been published in France: peripheral blood analysis should be performed in all newly diagnosed patients and followed by biannual peripheral blood analysis in infants until the age of 2 years. In order to describe the characteristics of these abnormalities in terms of their incidence, age of occurrence, evolution and relation to genotype, we are conducting a longitudinal prospective study whose aim is to analyze peripheral blood cell counts and smears at diagnosis and one year later. In patients \<3 years of age recruited at certain centers, biobanking of mononuclear cells will be performed. These data could yield a new insight into hematological anomalies in patients with RASopathies and thereby help physicians to determine the appropriate rhythm for hematological follow-up according to genotype.

CONDITIONS

Official Title

Hematological Anomalies in Children With Rasopathy

Who Can Participate

Age: 0 - 15Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age less than 16 years
  • Newly diagnosed with genetically confirmed rasopathy such as Noonan syndrome, type 1 neurofibromatosis, Noonan syndrome with multiple lentigines, CBL syndrome, Costello syndrome, cardiofaciocutaneous syndrome, or Legius syndrome
  • Germline mutation in genes including PTPN11, SOS1, NRAS, RAF1, BRAF, SHOC2, MEK1, MEK2, CBL, NF1, SPRED1, KRAS, HRAS, SHOC2, LZTR1, SOS2, RIT1, RASA2, RRAS, PPP1CB, or new genes discovered during recruitment
  • No history of hematological malignancy
  • Written informed consent from parents
  • Health insurance coverage
Not Eligible

You will not qualify if you...

  • History of malignant hematological pathology

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 14 locations

1

CHU Angers

Angers, France

Actively Recruiting

2

CHU Caen

Caen, France

Actively Recruiting

3

CHU Lille

Lille, France

Actively Recruiting

4

CHU Lyon

Lyon, France

Actively Recruiting

5

CHU Marseille - Hôpital de la Timone

Marseille, France

Actively Recruiting

6

CHU Montpellier

Montpellier, France

Actively Recruiting

7

CHU Nantes

Nantes, France

Actively Recruiting

8

Hôpital Necker APHP

Paris, France

Actively Recruiting

9

Hôpital Robert Debré APHP

Paris, France

Actively Recruiting

10

Hôpital Robert Debré APHP

Paris, France

Actively Recruiting

11

Hôpital Trousseau APHP

Paris, France

Actively Recruiting

12

CHU Rennes

Rennes, France

Actively Recruiting

13

CHU Strasbourg

Strasbourg, France

Actively Recruiting

14

CHU Toulouse

Toulouse, France

Actively Recruiting

Loading map...

Research Team

M

Marion STRULLU, MD

CONTACT

J

Jérôme Lambert, MD PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here